Business Offer

2017/07/31

United States

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. The fusion protein-directed IL2 therapy induces a T cell-dependent host immune response capable of eradicating established colon cancer metastases in an animal tumor model.

This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EpCAM IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EpCAM as well as the biological activity of IL2. The fusion protein-directed IL2 therapy induces a T cell-dependent host immune response capable of eradicating established colon cancer metastases in an animal tumor model. The IL2 component of the IC allows IL2Rs to function not only as receptors for this cytokine but also as facilitators of peritoneal NK cell binding to IC-coated tumor cells. This immunocytokine was designed for treating solid tumor. http://www.creativebiolabs.net/Anti-EpCAM-Immunocytokine-IgG-huKS-IL2-22501.htm

[RequestAdvantages]

[RequestComments]

387

Creative Biolabs